Please ensure Javascript is enabled for purposes of website accessibility
Maxx Chatsko

Maxx Chatsko

XMFBlacknGoldX

Maxx has been a contributor to Fool.com since 2013. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering.

Recent articles

chalkboard stock down pink

Here's Why Deciphera Pharmaceuticals Tumbled Today

The company announced a public stock offering as it prepares for a potential regulatory approval in 2020.


297 head in sand

Twist Bioscience Pursues Growth at All Costs. How Long Will Investors Tolerate It?

The biggest source of uncertainty has been removed, allowing Wall Street to focus on the company's growth and financials. But investors should be careful what they wish for.


433 money grab

2 Stocks to Buy and Hold for Decades

These two stocks are supported by solid long-term opportunities, but they couldn't be more different.


600 businessman winning

2 Stocks to Hold for the Next 20 Years

The world's leading lithium producer and one of America's greenest electric utilities are great investments for investors with a long-term mindset.


happy investor

Here's Why Adverum Biotechnologies Is Soaring Today

Interim results from an early-stage study of its wet age-related macular degeneration treatment look promising.

410 binoculars kid

Stocks to Watch in February

These three stocks have major events coming up this month -- and it's not just the release of earnings that investors will be watching.


201 wind turbines mountain

2 Recession-Ready Stocks to Buy Right Now

Recession or not, these two utilities will keep delivering the electricity, natural gas, and water that make modern life possible.


stock down erased chalkboard

Here's Why Sorrento Therapeutics Shares Jumped 13.3% in January

The pharmaceutical stock soared after being approached for an acquisition, but has tanked in the weeks since management announced it has declined the offer.


multiple lines down

Here's Why International Paper Stock Fell 11.6% in January

Investors initially were displeased with full-year 2019 operating results, but shares have bounced back in February.


chalkboard stock down pink

Here's Why Incyte Stock Tumbled 16.3% in January

A failed study disappointed investors, but the company's pipeline should withstand the blow.

324 rooftop solar install

Here's Why Enphase Energy Stock Jumped 20.6% in January

Investors continue to gobble up shares of the fast-growing company.


arrow up shelves

Here's Why Collegium Pharmaceutical Rose as Much as 20.7% Today

The speciality pharmaceutical company purchased the full rights to an important drug product.


563 shocked phone

Here's Why Zogenix Took a Tumble Today

Despite reports of positive late-stage results for an important drug candidate, Wall Street was hoping for more.


stock down erased chalkboard

Here's Why Arrowhead Pharmaceuticals Fell 33.9% in January

Investors began to question the excessive market valuation for the early-stage biopharma, but the company still has plenty of potential.


445 lng aerial

Here's Why LNG Shipping Stocks Fell as Much as 52.1% Today

GasLog offered mixed comments on the state of the market, announced major impairment charges, and slashed its distribution.

299 medical stock

Here's Why Cardinal Health Rose as Much as 13.7% Today

The healthcare company reported solid quarterly earnings and raised its fiscal full-year 2020 guidance.


009 merger acquisition getty

Catalent Makes $315 Million Acquisition in Cellular Medicine

The drug manufacturer is doubling down on biologic drugs to grow profits, but not all of the additional earnings will trickle down the income statement for individual investors.


stock down angry fist

Here's Why Ziopharm Oncology Fell as Much as 14.0% Today

The small-cap pharmaceutical company announced the pricing of a public stock offering.


600 scientist microscope

Here's Why CRISPR Stocks Fell in January

What's expected to be a busy year for CRISPR stocks started off with a thud, not a bang.


079 wind turbines hill

3 Reasons Wind Power Is Poised for a Breakout in 2020

The wind drought that plagued investors in 2018 and 2019 is likely over, but that's only one of the factors to consider.